We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
+45.54%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$132M
AUM Growth
-$48M
(-27%)
Cap. Flow
-$51.8M
Cap. Flow
% of AUM
-39.17%
Top 10 Holdings %
Top 10 Hldgs %
58.69%
Holding
110
New
19
Increased
5
Reduced
6
Closed
42
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xenon Pharmaceuticals
XENE
|
+$9.06M |
| 2 |
GRI
GRI Bio
GRI
|
+$8.89M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
+$5.73M |
| 4 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$4.5M |
| 5 |
Jasper Therapeutics
JSPR
|
+$4.26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLU
BELLUS Health Inc.
BLU
|
+$8.15M |
| 2 |
ACLX
Arcellx
ACLX
|
+$4.62M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$4.58M |
| 4 |
Glaukos
GKOS
|
+$4.56M |
| 5 |
Penumbra
PEN
|
+$4.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.25% |
| 2 | Financials | 1.18% |
| 3 | Technology | 1.18% |
| 4 | Communication Services | 0.44% |
| 5 | Materials | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $11.7M | 8.87% |
305,000
| – | – |
|
|
ATXS
2
DELISTED
Astria Therapeutics
ATXS
| $11.2M | 8.49% |
1,347,088
| – | – |
|
|
IMGN
3
DELISTED
Immunogen Inc
IMGN
| $9.15M | 6.93% |
+485,000
| New | +$5.73M |
|
4
ADMA Biologics
ADMA
$2.04B
| $8.78M | 6.65% |
2,380,000
-490,000
| -17% | -$1.82M |
|
|
5
Xenon Pharmaceuticals
XENE
$6.28B
| $8.78M | 6.64% |
+228,000
| New | +$9.06M |
|
|
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
| $7.32M | 5.54% |
668,702
+48,702
| +8% | +$453K |
|
7
Xtant Medical Holdings
XTNT
$59.7M
| $5.79M | 4.38% |
6,227,559
| – | – |
|
8
Harmony Biosciences
HRMY
$2.07B
| $5.27M | 3.99% |
149,889
+119,889
| +400% | +$4.14M |
|
|
GRI
9
GRI Bio
GRI
$2.53M
| $5.01M | 3.79% |
+27
| New | +$8.89M |
|
10
MoonLake Immunotherapeutics
MLTX
$1.59B
| $4.49M | 3.4% |
+88,000
| New | +$2.37M |
|
|
RETA
11
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $4.23M | 3.2% |
41,485
+6,485
| +19% | +$614K |
|
12
Amylyx Pharmaceuticals
AMLX
$2.17B
| $3.99M | 3.02% |
185,000
| – | – |
|
|
13
Jasper Therapeutics
JSPR
$21.1M
| $3.93M | 2.97% |
+286,800
| New | +$4.26M |
|
|
ICPT
14
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $3.57M | 2.7% |
+323,000
| New | +$4.5M |
|
15
PUT
BridgeBio Pharma
BBIO
$16.8B
| $3.44M | 2.6% |
+200,000
| New | +$3.01M |
|
16
Sarepta Therapeutics
SRPT
$1.63B
| $3.21M | 2.43% |
+28,000
| New | +$3.61M |
|
17
Replimune Group
REPL
$449M
| $3.02M | 2.28% |
130,000
-18,000
| -12% | -$352K |
|
18
Phathom Pharmaceuticals
PHAT
$930M
| $2.97M | 2.25% |
+207,432
| New | +$2.39M |
|
19
Axsome Therapeutics
AXSM
$12.1B
| $2.87M | 2.18% |
+40,000
| New | +$2.95M |
|
20
Olema Pharmaceuticals
OLMA
$1.01B
| $2.8M | 2.12% |
+310,000
| New | +$1.87M |
|
21
Cogent Biosciences
COGT
$6.95B
| $2.78M | 2.11% |
+235,000
| New | +$2.7M |
|
22
Crinetics Pharmaceuticals
CRNX
$8.88B
| $2.43M | 1.84% |
135,000
+35,000
| +35% | +$698K |
|
23
Vera Therapeutics
VERA
$2.39B
| $1.93M | 1.46% |
120,000
-166,000
| -58% | -$1.5M |
|
24
Dyne Therapeutics
DYN
$4.28B
| $1.74M | 1.32% |
155,000
| – | – |
|
25
Praxis Precision Medicines
PRAX
$8.25B
| $1.64M | 1.24% |
+95,000
| New | +$1.45M |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Altium Capital Management held 110 positions worth $132M, down 27% from $180M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Altium Capital Management withdrew a net $51.8M in Q2 2023, closing 42 positions and reducing 6 holdings. Its most notable exit was BELLUS Health Inc., an estimated $8.15M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Financials and Technology.
Against the trend, Altium Capital Management opened a new position in Xenon Pharmaceuticals worth $8.78M.
- Altium Capital Management's largest Q2 2023 buy was Xenon Pharmaceuticals: 228,000 shares worth $8.78M.
- Altium Capital Management added most to Harmony Biosciences in Q2 2023, an estimated $4.14M increase.
- Altium Capital Management's biggest Q2 2023 reduction was ADMA Biologics, cutting an estimated $1.82M.
- Altium Capital Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $8.15M.
- Altium Capital Management's ten largest holdings make up 59% of its $132M portfolio in Q2 2023.
- Altium Capital Management opened 19 new positions and closed 42 in Q2 2023.
- Altium Capital Management's portfolio value fell 27% quarter-over-quarter to $132M.
Based on Altium Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.